Background

Ned is a medical doctor and research assistant with a particular interest in hepatitis C. In 2017, he completed an honours thesis examining the acceptability of rapid, point-of-care hepatitis C testing for people who inject drugs. Since then, Ned has continued to work within the viral hepatitis elimination group. In 2021, Ned was awarded a Fulbright Scholarship to undertake further study at Columbia University.

Appointments

• 2017 – present: Research assistant, Burnet Institute

Positions

• 2021: Medical lead, COVID-19 Division – Victorian Department of Health
• 2020: Basic Physician Trainee (BPT1), Alfred Health
• 2019: Intern, Alfred Health
• 2018: Co-chair, Red Party Victoria
• 2017: Teaching associate, School of Public Health and Preventative Medicine, Monash University

Qualifications

• 2018: MBBS(Hons), Monash University
• 2017: BMedSc(Hons), Monash University

Awards

• 2021: Fulbright Future Scholarship
• 2018: Hatem Salem Award for Medical Student Research Excellence, Monash University
• 2018: Conference academic scholarship, International Network on Hepatitis in Substance Users
• 2018: John Snow Scholarship, Royal Australasian College of Physicians
• 2018: Scholarship to attend the Academy for Emerging Leaders in Patient Safety, NSW Clinical Excellence Commission
• 2016: Top Summer Research Student Award, School of Public Health and Preventative Medicine, Monash University
• 2015: Summer Research Scholarship, School of Public Health and Preventative Medicine, Monash University
• 2013: Sir John Monash Scholarship for Excellence, Monash University

Projects (1)

Current (1)

• 

  The elimination of hepatitis C as a global public health threat

Publications (5)

2021 (1)

• "It's time!": A qualitative exploration of the acceptability of hepatitis C notification systems to help eliminate hepatitis C.
  Walker S, Wallace J, Latham N, Saich F, Pedrana A, Hellard M, Treloar C, Marukutira T, Higgs P, Doyle J, Stoové M
  Int J Drug Policy. 2021 May; 97:103280

2020 (1)

• Treading lightly: Finding the best way to use public health surveillance of hepatitis C diagnoses to increase access to cure.
  Stoové M, Wallace J, Higgs P, Pedrana A, Goutzamanis S, Latham N, Scott N, Treloar C, Crawford S, Doyle J, Hellard M
  Int J Drug Policy. 2020 Jan; 75:102596

2019 (3)

• Staying hepatitis C negative: a systematic review and meta-analysis of cure and reinfection in people who inject drugs.
  Latham NH, Doyle JS, Palmer AY, Vanhommerig JW, Agius P, Goutzamanis S, Li Z, Pedrana A, Gottfredsson M, Bouscaillou J, Luhmann N, Mazhnaya A, Altice FL, Saeed S, Klein M, Falade-Nwulia OO, Aspinall E, Hutchinson S, Hellard ME, Sacks-Davis R
  Liver Int. 2019 Dec; 39(12):2244-2260
• Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study.
  Williams B, Howell J, Doyle J, Thompson AJ, Draper B, Layton C, Latham N, Bramwell F, Membrey D, Mcpherson M, Roney J, Stoové M, Hellard ME, Pedrana A
  Int J Drug Policy. 2019 Oct; 72:91-98
• Community-based, point-of-care hepatitis C testing: perspectives and preferences of people who inject drugs.
  Latham NH, Pedrana A, Doyle JS, Howell J, Williams B, Higgs P, Thompson AJ, Hellard ME
  J Viral Hepat. 2019 Feb; 26(7):919-922

News Articles (1)

2021 (1)

• Prestigious US scholarship for Burnet researcher